USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Dec 31, 2021 (est) | Sep 30, 2021 | - | $-1.75 | $-2.10 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Dec 31, 2021 (est) | Sep 30, 2021 | - | $3.11M | $1.46M |
Aptevo Therapeutics Inc's next estimated earnings date (based on same quarter last year's date) is Dec 31, 2021 for the fiscal quarter ending Sep 30, 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 2 | $-1.40 | $-1.76 | $-1.05 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $-5.66 | $-5.66 | $-5.66 |
| Dec 2022 | 1 | $-5.18 | $-5.18 | $-5.18 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-1.40 | $-1.22 | $-1.22 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-5.66 | $-6.39 | $-6.39 |
| Dec 2022 | 0 / 0 | $-5.18 | $-5.19 | $-5.19 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 2 | $4.25M | $4.00M | $4.50M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 2 | $13.41M | $13.00M | $13.83M |
| Dec 2022 | 2 | $17.34M | $14.69M | $20.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $-1.85 | $-1.75 | 5.15% |
| May 11, 2021 | Mar 2021 | $-1.62 | $-1.64 | -1.23% |
| Mar 31, 2021 | Dec 2020 | $-1.51 | $-1.92 | -26.88% |
| Dec 31, 2020 | Sep 2020 | $-2.05 | $-2.10 | -2.44% |
| Aug 14, 2020 | Jun 2020 | $-2.06 | $-2.10 | -1.94% |
| May 13, 2020 | Mar 2020 | $-2.29 | $0.89 | 138.86% |
| Mar 25, 2020 | Dec 2019 | $-3.59 | $-1.26 | 64.93% |
| Nov 7, 2019 | Sep 2019 | $-3.36 | $-2.24 | 33.33% |
| Aug 9, 2019 | Jun 2019 | $-3.57 | $-4.20 | -17.65% |
| May 9, 2019 | Mar 2019 | $-6.16 | $-6.16 | - |
| Mar 18, 2019 | Dec 2018 | $-7.47 | $-8.68 | -16.25% |
| Nov 14, 2018 | Sep 2018 | $-8.03 | $-7.84 | 2.33% |
| Aug 9, 2018 | Jun 2018 | $-9.03 | $-8.12 | 10.08% |
| May 10, 2018 | Mar 2018 | $-7.77 | $-8.82 | -13.51% |
| Mar 13, 2018 | Dec 2017 | $-4.48 | $-6.44 | -43.75% |
| Nov 9, 2017 | Sep 2017 | $31.50 | $24.50 | -22.22% |
| Aug 10, 2017 | Jun 2017 | $-8.54 | $-7.42 | 13.11% |
| May 12, 2017 | Mar 2017 | $-9.94 | $-8.74 | 12.11% |
| Mar 31, 2017 | Dec 2016 | $-6.16 | $-5.64 | 8.41% |
| Nov 14, 2016 | Sep 2016 | $-8.96 | $-11.10 | -23.84% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 31, 2021 | Dec 2020 | $-4.56 | $-5.23 | - |
| Mar 25, 2020 | Dec 2019 | $-1.13 | $-13.86 | - |
| Mar 18, 2019 | Dec 2018 | $-2.30 | $-33.46 | - |
| Mar 13, 2018 | Dec 2017 | $0.43 | $1.90 | 342.79% |
| Mar 31, 2017 | Dec 2016 | - | $-16.74 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $900.00K | $3.11M | 3.46% |
| May 11, 2021 | Mar 2021 | $2.42M | $2.42M | 1.00% |
| Mar 31, 2021 | Dec 2020 | $1.74M | $2.37M | 1.36% |
| Dec 31, 2020 | Sep 2020 | $560.00K | $1.46M | 2.61% |
| Aug 14, 2020 | Jun 2020 | $260.00K | $473.00K | 1.82% |
| May 13, 2020 | Mar 2020 | $5.17M | $9.03M | 1.75% |
| Mar 25, 2020 | Dec 2019 | $9.74M | $9.03M | 0.93% |
| Nov 7, 2019 | Sep 2019 | $9.00M | $9.01M | 1.00% |
| Aug 9, 2019 | Jun 2019 | $7.04M | $7.36M | 1.05% |
| May 9, 2019 | Mar 2019 | $6.77M | $7.02M | 1.04% |
| Mar 18, 2019 | Dec 2018 | $6.28M | $6.35M | 1.01% |
| Nov 14, 2018 | Sep 2018 | $6.93M | $5.82M | 0.84% |
| Aug 9, 2018 | Jun 2018 | $4.17M | $6.83M | 1.64% |
| May 10, 2018 | Mar 2018 | $3.37M | $4.07M | 1.21% |
| Mar 13, 2018 | Dec 2017 | $3.00M | $2.82M | 0.94% |
| Nov 9, 2017 | Sep 2017 | - | $6.17M | - |
| Aug 10, 2017 | Jun 2017 | - | $10.76M | - |
| May 12, 2017 | Mar 2017 | - | $7.41M | - |
| Mar 31, 2017 | Dec 2016 | - | $8.77M | - |
| Nov 14, 2016 | Sep 2016 | - | $9.40M | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 31, 2021 | Dec 2020 | $3.68M | $4.31M | 17.09% |
| Mar 25, 2020 | Dec 2019 | $33.13M | $32.42M | -2.13% |
| Mar 18, 2019 | Dec 2018 | $23.00M | $23.07M | 0.29% |
| Mar 13, 2018 | Dec 2017 | $27.35M | $14.66M | -46.41% |
| Mar 31, 2017 | Dec 2016 | - | $36.43M | - |
APVO's next estimated earnings date (based on same quarter last year's report date) is Dec 31, 2021 for the fiscal quarter ending Sep 30, 2021.
Aptevo Therapeutics Inc's previous earnings date was Aug 12, 2021 for its fiscal quarter ended Jun 30, 2021.
APVO's earnings per share (EPS) was $-1.75, beating the consensus analysts forecast of $-1.85 by 5.15%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by 6.71%, and higher than the same period a year before (Jun 2020) by -16.67%.
Revenues were $3.11M, better than the forecast of $900.00K by 245.56%, up by 28.46% from the previous quarter , and up by 557.51% from the same period last year.
The company reported a net income of $-7.93M.Free cash flow for the quarter was $-5.44M , compared to $-7.70M last quarter and $-4.63M a year before.
APVO ended the quarter with $16.86M in total debt, a decrease of -0.24% compared to the previous quarter, and an increase of 490.09% compared to the same quarter a year before.
Aptevo Therapeutics Inc's previous annual earnings date was Mar 31, 2021 for its fiscal year ended Dec 31, 2020.
APVO's earnings per share (EPS) was $-5.23, missing the consensus analysts forecast of $-4.56 by 14.69% , and higher than the previous year's EPS (Dec 2019) by -62.27%.
Revenues were $4.31M, better than the forecast of $3.68M by 17.09%, and down by -86.71% from previous year's revenue.
The company reported a net income of $-17.75M.
Aptevo Therapeutics Inc reported a free cash flow of $-29.41M for its fiscal year, compared to $-42.54M a year ago.
The company ended the fiscal year with $10.00M in total debt, a decrease of -56.88% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.